title: Effect of oncotic pressure of diaspirin cross-linked hemoglobin (DCLHb) on brain injury after temporary focal cerebral ischemia in rats.
abstract: Previous studies have shown that diaspirin cross-linked hemoglobin (DCLHb, 10 g/dL) decreases cerebral ischemia and the resultant injury in a dose-dependent manner, requiring large volumes of DCLHb for maximum efficacy. We assessed the effect of a more concentrated (20 g/dL) and more hyperoncotic preparation of DCLHb on cerebral infarction volume. Immediately after middle cerebral artery occlusion, rats were randomized to one of the following groups: Control, hematocrit not manipulated; 10/Hb, hematocrit decreased to 30% with 10% DCLHb (oncotic pressure 43 mm Hg); 7.5/Alb, hematocrit decreased to 30% with 7.5% albumin (oncotic pressure 43 mm Hg); 20/Hb, the same dose of DCLHb (20%, oncotic pressure 129 mm Hg) as the 10/HB group (half the volume); or 15/Alb, the same dose of albumin (15%, oncotic pressure 130 mm Hg) as the 7.5/Alb group half the volume). After 90 min of ischemia, 72 h of reperfusion was allowed. Infarction volume (mm3, mean +/- sd) was less in the DCLHb groups (10/Hb = 79 +/- 17; 20/HB = 51 +/- 14) than the oncotically matched albumin groups (7.5/Alb = 124 +/- 21; 15/Alb = 85 +/- 18) and the Control group (135 +/- 17) (P < 0.05). These data indicate that in this model of cerebral ischemia, DCLHb decreases ischemic brain injury more effectively than albumin, and that a hyperoncotic preparation of DCLHb is preferable.
authors.affiliation: Department of Anesthesiology, Loma Linda University, California 92354, USA.
authors.forename: D J
authors.initials: DJ
authors.lastname: Cole
authors.forename: J C
authors.initials: JC
authors.lastname: Drummond
authors.forename: P M
authors.initials: PM
authors.lastname: Patel
authors.forename: J C
authors.initials: JC
authors.lastname: Nary
authors.forename: R L
authors.initials: RL
authors.lastname: Applegate
mesh_terms: D000818:Animals; D001241:Aspirin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001810:Blood Volume; D001921:Brain / Q000187:drug effects* / Q000473:pathology; D002544:Cerebral Infarction / Q000473:pathology / Q000517:prevention & control*; D004396:Coloring Agents; D004305:Dose-Response Relationship, Drug; D005078:Exchange Transfusion, Whole Blood; D006400:Hematocrit; D006438:Hemodilution; D006454:Hemoglobins / Q000008:administration & dosage / Q000627:therapeutic use*; D002546:Ischemic Attack, Transient / Q000188:drug therapy*; D008297:Male; D009997:Osmotic Pressure; D011897:Random Allocation; D051381:Rats; D011918:Rats, Inbred SHR; D015424:Reperfusion; D012709:Serum Albumin / Q000008:administration & dosage / Q000627:therapeutic use; D013778:Tetrazolium Salts
chemical_list: D004396:Coloring Agents; D006454:Hemoglobins; D012709:Serum Albumin; D013778:Tetrazolium Salts; C009591:triphenyltetrazolium; C083478:diaspirin-cross-linked hemoglobin; D001241:Aspirin